<DOC>
	<DOCNO>NCT00002326</DOCNO>
	<brief_summary>To study safety , tolerance , pharmacokinetics , anti-HIV effect combination zidovudine ( AZT ) PMEA ( adefovir ) therapy .</brief_summary>
	<brief_title>The Safety Effectiveness Zidovudine Plus Adefovir HIV-Infected Patients</brief_title>
	<detailed_description>Patients receive AZT daily intravenous PMEA three time weekly 4 week . An MTD define regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylactic therapy aerosolize pentamidine , oral trimethoprim/sulfamethoxazole ( Bactrim , Septra ) dapsone , fluconazole ketoconazole IF stable regimen least 4 week prior study entry . Patients must : HIV seropositivity . Mean CD4 count &lt; = 500 cells/mm3 . Been receive AZT 500 mg daily least 4 week prior study entry . Life expectancy least 3 month . NOTE : Kaposi 's sarcoma permit provided patient receive systemic therapy KS within past 4 week . Patients history another malignancy must disease free 6 month prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Inadequate venous access . Active , serious infection ( HIV infection ) require parenteral antibiotic therapy . Clinically significant cardiac disease , include symptom ischemia , congestive heart failure , clinically significant arrhythmia . Active malignancy Kaposi 's sarcoma . Mental incapacity illness may affect compliance . Concurrent Medication : Excluded : ddI ddC . Interferon alpha . Ganciclovir . Foscarnet . Diuretics . Investigational agent include d4T . Chemotherapeutic agent . Amphotericin B. Aminoglycoside antibiotic . Other nephrotoxic agent . Immunomodulatory agent . Parenteral therapy active , serious infection ( HIV infection ) . Prior Medication : Excluded within 2 week prior study entry : ddI ddC . Interferon alpha . Ganciclovir . Foscarnet . Diuretics . Investigational agent include d4T . Chemotherapeutic agent . Amphotericin B. Aminoglycoside antibiotic . Other nephrotoxic agent . Immunomodulatory agent . Excluded within 4 week prior study entry : Systemic therapy Kaposi 's sarcoma . Required : AZT stable dose least 4 week prior study entry . Current use illicit drug ( e.g. , heroin cocaine ) . Ingestion substantial alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 1995</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Adenine</keyword>
</DOC>